Patients with atopic dermatitis with filaggrin loss-of-function mutations show good but lower responses to immunosuppressive treatment

E. Roekevisch; M. M. G. Leeflang; M. E. Schram; L. E. Campbell; W. H. Irwin McLean; S. Kezic; J. D. Bos; P. I. Spuls; M. A. Middelkamp-Hup

doi:10.1111/bjd.15191

Patients with atopic dermatitis with filaggrin loss-of-function mutations show good but lower responses to immunosuppressive treatment

E. Roekevisch (Lead / Corresponding author), M. M. G. Leeflang, M. E. Schram, L. E. Campbell, W. H. Irwin McLean, S. Kezic, J. D. Bos, P. I. Spuls, M. A. Middelkamp-Hup

Research output: Contribution to journal › Letter › peer-review

10 Citations (Scopus)

334 Downloads (Pure)

Abstract

Filaggrin (FLG) mutations are a strong risk factor to develop atopic dermatitis (AD). However, the relationship between FLG mutations and treatment outcome in AD has not been thoroughly studied. To investigate whether FLG mutations influence immunosuppressive treatment outcome in AD, we studied the effect of FLG mutations in patients with severe AD participating in a single blinded randomized controlled trial (RCT) with methotrexate (MTX) or azathioprine (AZA) during a 24 weeks treatment regimen.((1)) Two years after randomization buccal mucosa swabs were collected from 36 of the 42 RCT patients (86%) to determine the FLG genotype status (R501X, 2282del4, R2447X, S3247X and 3321delA mutations). This article is protected by copyright. All rights reserved.

Original language	English
Pages (from-to)	1745-1746
Number of pages	2
Journal	British Journal of Dermatology
Volume	177
Issue number	6
Early online date	19 Nov 2016
DOIs	https://doi.org/10.1111/bjd.15191
Publication status	Published - 8 Jan 2018

Keywords

Atopic dermatitis
Atopic eczema
Filaggrin
Skin barrier
Mutation
Azathioprine
Methotrexate
Immunosuppressive treatment
Treatment outcome

ASJC Scopus subject areas

Dermatology

Access to Document

10.1111/bjd.15191

Author Accepted ManuscriptAccepted author manuscript, 429 KB

Cite this

Roekevisch, E., Leeflang, M. M. G., Schram, M. E., Campbell, L. E., Irwin McLean, W. H., Kezic, S., Bos, J. D., Spuls, P. I., & Middelkamp-Hup, M. A. (2018). Patients with atopic dermatitis with filaggrin loss-of-function mutations show good but lower responses to immunosuppressive treatment. British Journal of Dermatology, 177(6), 1745-1746. https://doi.org/10.1111/bjd.15191

@article{fd20c00da1f74c629590ed3e8ad690ff,

title = "Patients with atopic dermatitis with filaggrin loss-of-function mutations show good but lower responses to immunosuppressive treatment",

abstract = "Filaggrin (FLG) mutations are a strong risk factor to develop atopic dermatitis (AD). However, the relationship between FLG mutations and treatment outcome in AD has not been thoroughly studied. To investigate whether FLG mutations influence immunosuppressive treatment outcome in AD, we studied the effect of FLG mutations in patients with severe AD participating in a single blinded randomized controlled trial (RCT) with methotrexate (MTX) or azathioprine (AZA) during a 24 weeks treatment regimen.((1)) Two years after randomization buccal mucosa swabs were collected from 36 of the 42 RCT patients (86%) to determine the FLG genotype status (R501X, 2282del4, R2447X, S3247X and 3321delA mutations). This article is protected by copyright. All rights reserved.",

keywords = "Atopic dermatitis, Atopic eczema, Filaggrin, Skin barrier, Mutation, Azathioprine, Methotrexate, Immunosuppressive treatment, Treatment outcome",

author = "E. Roekevisch and Leeflang, {M. M. G.} and Schram, {M. E.} and Campbell, {L. E.} and {Irwin McLean}, {W. H.} and S. Kezic and Bos, {J. D.} and Spuls, {P. I.} and Middelkamp-Hup, {M. A.}",

year = "2018",

month = jan,

day = "8",

doi = "10.1111/bjd.15191",

language = "English",

volume = "177",

pages = "1745--1746",

journal = "British Journal of Dermatology",

issn = "0007-0963",

publisher = "Oxford University Press",

number = "6",

}

Patients with atopic dermatitis with filaggrin loss-of-function mutations show good but lower responses to immunosuppressive treatment. / Roekevisch, E. (Lead / Corresponding author); Leeflang, M. M. G.; Schram, M. E. et al.
In: British Journal of Dermatology, Vol. 177, No. 6, 08.01.2018, p. 1745-1746.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Patients with atopic dermatitis with filaggrin loss-of-function mutations show good but lower responses to immunosuppressive treatment

AU - Roekevisch, E.

AU - Leeflang, M. M. G.

AU - Schram, M. E.

AU - Campbell, L. E.

AU - Irwin McLean, W. H.

AU - Kezic, S.

AU - Bos, J. D.

AU - Spuls, P. I.

AU - Middelkamp-Hup, M. A.

PY - 2018/1/8

Y1 - 2018/1/8

N2 - Filaggrin (FLG) mutations are a strong risk factor to develop atopic dermatitis (AD). However, the relationship between FLG mutations and treatment outcome in AD has not been thoroughly studied. To investigate whether FLG mutations influence immunosuppressive treatment outcome in AD, we studied the effect of FLG mutations in patients with severe AD participating in a single blinded randomized controlled trial (RCT) with methotrexate (MTX) or azathioprine (AZA) during a 24 weeks treatment regimen.((1)) Two years after randomization buccal mucosa swabs were collected from 36 of the 42 RCT patients (86%) to determine the FLG genotype status (R501X, 2282del4, R2447X, S3247X and 3321delA mutations). This article is protected by copyright. All rights reserved.

AB - Filaggrin (FLG) mutations are a strong risk factor to develop atopic dermatitis (AD). However, the relationship between FLG mutations and treatment outcome in AD has not been thoroughly studied. To investigate whether FLG mutations influence immunosuppressive treatment outcome in AD, we studied the effect of FLG mutations in patients with severe AD participating in a single blinded randomized controlled trial (RCT) with methotrexate (MTX) or azathioprine (AZA) during a 24 weeks treatment regimen.((1)) Two years after randomization buccal mucosa swabs were collected from 36 of the 42 RCT patients (86%) to determine the FLG genotype status (R501X, 2282del4, R2447X, S3247X and 3321delA mutations). This article is protected by copyright. All rights reserved.

KW - Atopic dermatitis

KW - Atopic eczema

KW - Filaggrin

KW - Skin barrier

KW - Mutation

KW - Azathioprine

KW - Methotrexate

KW - Immunosuppressive treatment

KW - Treatment outcome

U2 - 10.1111/bjd.15191

DO - 10.1111/bjd.15191

M3 - Letter

C2 - 27864930

SN - 0007-0963

VL - 177

SP - 1745

EP - 1746

JO - British Journal of Dermatology

JF - British Journal of Dermatology

IS - 6

ER -

Patients with atopic dermatitis with filaggrin loss-of-function mutations show good but lower responses to immunosuppressive treatment

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this